Content matching 'parkinsons'
A team of scientists led by The New York Stem Cell Foundations (NYCSF) Research Institute recreated a human stem cell model of Parkinson’s disease in a dish.
Preparing for first human trial of iPSC-derived cells for Parkinson’s disease: an interview with Jun Takahashi
Scientists at Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have successfully integrated functional neurons reprogrammed from skin cells into mouse brains, with long-term stability.
Cell therapy weekly: Japanese scientists target Parkinson’s disease with iPSC-derived dopaminergic progenitors
Free to access editorial from our latest Regenerative Medicine issue by Janelle Drouin-Ouellet and Roger A Barker
Noninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson's disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer's and other CNS disorders.
Regenerative medicine and therapeutic cell treatment of disorders of the brain and spinal cord are hindered by the blood-brain barrier. Invasive implantation of therapeutic cells in the brain, including stem cells and immune cells, is both risky and impractical. Noninvasive intranasal cell delivery to the CNS provides a solution to this problem.